Techniques to circumvent or abrogate acquired resistance to ganitumab therapy.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Writer ManuscriptMol Most cancers Ther. Writer manuscript; available in PMC 2014 April 01.Fahrenholtz et al.PageSupplementary MaterialRefer to Internet model on PubMed Central for supplementary substance.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Creator ManuscriptAcknowledgmentsWe thank Dr. Maria Mudyri (University of California Davis) for her knowledge together with the CWR-R1 cell line and Dr. Wayne Balkan (College of Miami) for instruction and assistance with mouse xenografts and surgery. We also thank Drs. Young-Ah Chung, Elaina Cajulis, and Frank Calzone of Amgen Inc. for technical assistance, skills and guidance. Grant Aid: Funding for this analysis was 465-99-6 Purity furnished by Amgen Inc and NIH grant R01CA132200 (KLB). CDF was supported by NIH teaching grant T32-HL007188.Works Cited1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Most cancers J Clin. 2010; 60:27700. [PubMed: 20610543] two. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of expansion aspect signaling in human hepatocellular carcinoma. Oncogene. 2006; twenty five:378700. [PubMed: 16799620] three. Mendivil A, Zhou C, Cantrell LA, Gehrig PA, Malloy KM, Blok LJ, et al. AMG 479, a novel IGF-1-R antibody, 303997-35-5 In Vitro inhibits endometrial cancer mobile proliferation through disruption from the PI3KAkt and MAPK pathways. Reprod Sci. 2011; 18:8321. [PubMed: 21846689] four. Grothey A, Voigt W, Schober C, Muller T, Dempke W, Schmoll HJ. The role of insulin-like expansion issue I and its receptor in cell development, transformation, apoptosis, and chemoresistance in reliable tumors. J Cancer Res Clin Oncol. 1999; one hundred twenty five:1663. [PubMed: 10235470] 5. Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, et al. Efficacy of ganitumab (AMG 479), by yourself as well as in mixture with rapamycin, in Ewing’s and osteogenic sarcoma products. J Pharmacol Exp Ther. 2011; 337:6444. [PubMed: 21385891] 6. Yin M, Guan X, Liao Z, Wei Q. Insulin-like growth factor-1 receptor-targeted treatment for non-small cell lung cancer: a mini review. Am J Transl Res. 2009; 1:1014. [PubMed: 19956424] 7. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer. 2006; thirteen (Suppl one):S333. [PubMed: 17259557] 8. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like development aspects and neoplasia. Nat Rev Most cancers. 2004; 4:5058. [PubMed: 15229476] nine. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, et al. Serum insulin-like progress issue I: tumor marker or etiologic aspect A potential review of prostate most cancers between Finnish males. Cancer Res. 2003; 63:3991. [PubMed: 12873996] 10. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate most cancers models to androgen independence is related with enhanced expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 2001; 61:62760. [PubMed: 11507082] 11. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the variety 1 insulin-like expansion issue receptor is up-regulated in main prostate cancer and typically persists in metastatic illness. Cancer Res. 2002; 62:29420. [PubMed: 867164-40-7 References 12019176] twelve. Plymate SR, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, et al. An antibody targeting the type I insulin-like advancement variable receptor improves the castration-induced reaction in androgen-dependent prostate most cancers. Clin Cance.